NASDAQ:TNDMTandem Diabetes Care Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tandem Diabetes Care Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $84.69 +1.54 (+1.85 %) (As of 06/1/2020 04:00 PM ET) Add Compare Share Today's Range$82.22Now: $84.69▼$86.2650-Day Range$66.44MA: $80.03▼$90.9952-Week Range$43.69Now: $84.69▼$92.37Volume778,681 shsAverage Volume1.10 million shsMarket Capitalization$5.09 billionP/E RatioN/ADividend YieldN/ABeta0.59 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 Insulin Delivery System with Basal-IQ Technology; t:slim X2 with G5 Integration; and Tandem Device Updater that allows users to update their pump's software. In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; and various pump accessories. Its products in development include t:slim X2 with control IQ technology; t:sport insulin delivery system; and connected (mobile) health offerings. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 2.3 Analyst's Opinion Consensus RatingTandem Diabetes Care has received a consensus rating of Buy. The company's average rating score is 2.54, and is based on 7 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $86.92, Tandem Diabetes Care has a potential upside of 2.6% from its current price of $84.69.Amount of Analyst CoverageTandem Diabetes Care has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.5 Community Rank Outperform VotesTandem Diabetes Care has received 513 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTandem Diabetes Care has received 516 “underperform” votes. (Add your “underperform” vote.)Community SentimentTandem Diabetes Care has received 50.15% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Tandem Diabetes Care and other stocks. Vote “Outperform” if you believe TNDM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TNDM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTandem Diabetes Care does not currently pay a dividend.Dividend GrowthTandem Diabetes Care does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tandem Diabetes Care insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,848,680.00 in company stock.Percentage Held by InsidersOnly 6.00% of the stock of Tandem Diabetes Care is held by insiders.Percentage Held by Institutions93.44% of the stock of Tandem Diabetes Care is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tandem Diabetes Care are expected to grow in the coming year, from ($0.50) to $0.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tandem Diabetes Care is -256.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tandem Diabetes Care is -256.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTandem Diabetes Care has a P/B Ratio of 25.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.28 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TNDM Previous Symbol CUSIPN/A CIK1438133 Webwww.tandemdiabetes.com Phone858-366-6900Debt Debt-to-Equity Ratio0.09 Current Ratio2.82 Quick Ratio2.21Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$362.30 million Price / Sales14.05 Cash FlowN/A Price / Cash FlowN/A Book Value$3.30 per share Price / Book25.66Profitability EPS (Most Recent Fiscal Year)($0.22) Net Income$-24,750,000.00 Net Margins-4.22% Return on Equity-9.39% Return on Assets-5.51%Miscellaneous Employees1,043 Outstanding Shares60,100,000Market Cap$5.09 billion Next Earnings Date8/6/2020 (Estimated) OptionableOptionable NASDAQ:TNDM Rates by TradingView Receive TNDM News and Ratings via Email Sign-up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter. Tandem Diabetes Care (NASDAQ:TNDM) Frequently Asked Questions How has Tandem Diabetes Care's stock been impacted by COVID-19 (Coronavirus)? Tandem Diabetes Care's stock was trading at $66.33 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TNDM stock has increased by 27.7% and is now trading at $84.69. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Tandem Diabetes Care? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tandem Diabetes Care. When is Tandem Diabetes Care's next earnings date? Tandem Diabetes Care is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Tandem Diabetes Care. How were Tandem Diabetes Care's earnings last quarter? Tandem Diabetes Care Inc (NASDAQ:TNDM) posted its earnings results on Thursday, April, 30th. The medical device company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.07. The medical device company earned $97.90 million during the quarter, compared to analyst estimates of $84.49 million. Tandem Diabetes Care had a negative return on equity of 9.39% and a negative net margin of 4.22%. The business's quarterly revenue was up 49.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.40) earnings per share. View Tandem Diabetes Care's earnings history. When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work? Shares of Tandem Diabetes Care reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split. What guidance has Tandem Diabetes Care issued on next quarter's earnings? Tandem Diabetes Care issued an update on its second quarter 2020 After-Hours earnings guidance on Thursday, April, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $85 million, compared to the consensus revenue estimate of $85.26 million. What price target have analysts set for TNDM? 13 brokers have issued 12-month target prices for Tandem Diabetes Care's stock. Their forecasts range from $75.00 to $102.00. On average, they expect Tandem Diabetes Care's share price to reach $86.92 in the next year. This suggests a possible upside of 2.6% from the stock's current price. View analysts' price targets for Tandem Diabetes Care. Has Tandem Diabetes Care been receiving favorable news coverage? Media stories about TNDM stock have trended very positive recently, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tandem Diabetes Care earned a media sentiment score of 3.5 on InfoTrie's scale. They also assigned news stories about the medical device company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutTandem Diabetes Care. Who are some of Tandem Diabetes Care's key competitors? Some companies that are related to Tandem Diabetes Care include Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Integra Lifesciences (IART), Nevro (NVRO), ICU Medical (ICUI), Irhythm Technologies (IRTC), NuVasive (NUVA), Merit Medical Systems (MMSI) and Inovio Pharmaceuticals (INO). View all competitors. What other stocks do shareholders of Tandem Diabetes Care own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Square (SQ), Verizon Communications (VZ), Crispr Therapeutics (CRSP) and Roku (ROKU). Who are Tandem Diabetes Care's key executives? Tandem Diabetes Care's management team includes the following people: Mr. Kim D. Blickenstaff, Exec. Chairman (Age 67)Mr. John F. Sheridan, Pres & CEO (Age 64)Mr. Brian B. Hansen, Exec. VP & Chief Commercial Officer (Age 51)Ms. Leigh A. Vosseller, Exec. VP, CFO & Treasurer (Age 46)Mr. Manuel Jaime, Sr. VP of Technology & Digital Health What is Tandem Diabetes Care's stock symbol? Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM." Who are Tandem Diabetes Care's major shareholders? Tandem Diabetes Care's stock is owned by many different retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (11.29%), BlackRock Inc. (7.33%), Invesco Ltd. (2.77%), Federated Hermes Inc. (2.37%), State Street Corp (2.18%) and Brown Capital Management LLC (1.85%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Richard P Valencia and Susan Morrison. View institutional ownership trends for Tandem Diabetes Care. Which institutional investors are selling Tandem Diabetes Care stock? TNDM stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, TimesSquare Capital Management LLC, Deutsche Bank AG, Redmile Group LLC, Balyasny Asset Management LLC, Ardevora Asset Management LLP, Waddell & Reed Financial Inc., and Emerald Advisers LLC. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, and Leigh Vosseller. View insider buying and selling activity for Tandem Diabetes Care. Which institutional investors are buying Tandem Diabetes Care stock? TNDM stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Invesco Ltd., Russell Investments Group Ltd., Brown Capital Management LLC, Driehaus Capital Management LLC, Pictet Asset Management Ltd., Jennison Associates LLC, and BlackRock Inc.. View insider buying and selling activity for Tandem Diabetes Care. How do I buy shares of Tandem Diabetes Care? Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Tandem Diabetes Care's stock price today? One share of TNDM stock can currently be purchased for approximately $84.69. How big of a company is Tandem Diabetes Care? Tandem Diabetes Care has a market capitalization of $5.09 billion and generates $362.30 million in revenue each year. The medical device company earns $-24,750,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. Tandem Diabetes Care employs 1,043 workers across the globe. What is Tandem Diabetes Care's official website? The official website for Tandem Diabetes Care is www.tandemdiabetes.com. How can I contact Tandem Diabetes Care? Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected] This page was last updated on 6/2/2020 by MarketBeat.com Staff
